ARAY

Accuray Incorporated develops, manufactures, and sells advanced radiation therapy systems for the treatment of tumors. Headquartered in Madison, Wisconsin, the company operates globally through direct sales and distribution partnerships, serving hospitals and cancer treatment centers worldwide. Accuray's primary products include the CyberKnife System, a robotic stereotactic radiosurgery platform that delivers precise radiation beams to tumors throughout the body, and the Radixact System (formerly TomoTherapy), which provides image-guided intensity-modulated radiation therapy. The company generates revenue through initial system sales, typically ranging from $3 million to $7 million per unit, as well as recurring income from multi-year service contracts, software upgrades, and consumables. Accuray maintains a significant installed base of approximately 1,000 systems across more than 50 countries. The company employs around 600 people and operates manufacturing facilities in California and Wisconsin. Recent strategic initiatives include expanding its installed base in emerging markets, enhancing artificial intelligence capabilities in treatment planning software, and growing its recurring revenue stream through service contract renewals. Accuray competes in the radiation oncology market alongside larger medical device manufacturers, differentiating itself through specialized technology designed for complex and hard-to-reach tumors. The company reports annual revenue of approximately $400 million.